Achieving optimal treatment targets and minimal disease activity with upadacitinib for moderate-to-severe atopic dermatitis: integrated analysis of phase 3 studies (Measure Up 1 and 2) (2025)
- Authors:
- Autor USP: AOKI, VALERIA - FM
- Unidade: FM
- DOI: 10.1007/s13555-025-01485-0
- Subjects: DERMATITE DE CONTATO; RESULTADO DE TRATAMENTO; QUALIDADE DE VIDA; ENSAIO CLÍNICO; PLACEBOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Dermatology and Therapy
- ISSN: 2193-8210
- Volume/Número/Paginação/Ano: v. 15, n. 9, p. 2583-2594, 2025
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
SILVERBERG, Jonathan I. et al. Achieving optimal treatment targets and minimal disease activity with upadacitinib for moderate-to-severe atopic dermatitis: integrated analysis of phase 3 studies (Measure Up 1 and 2). Dermatology and Therapy, v. 15, n. 9, p. 2583-2594, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/89159. Acesso em: 06 maio 2026. -
APA
Silverberg, J. I., Gooderham, M., Katoh, N., Aoki, V., Pink, A. E., Binamer, Y., et al. (2025). Achieving optimal treatment targets and minimal disease activity with upadacitinib for moderate-to-severe atopic dermatitis: integrated analysis of phase 3 studies (Measure Up 1 and 2). Dermatology and Therapy, 15( 9), 2583-2594. doi:10.1007/s13555-025-01485-0 -
NLM
Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Glick B, Staubach P, Calimlim B, Li C. Achieving optimal treatment targets and minimal disease activity with upadacitinib for moderate-to-severe atopic dermatitis: integrated analysis of phase 3 studies (Measure Up 1 and 2) [Internet]. Dermatology and Therapy. 2025 ; 15( 9): 2583-2594.[citado 2026 maio 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/89159 -
Vancouver
Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Glick B, Staubach P, Calimlim B, Li C. Achieving optimal treatment targets and minimal disease activity with upadacitinib for moderate-to-severe atopic dermatitis: integrated analysis of phase 3 studies (Measure Up 1 and 2) [Internet]. Dermatology and Therapy. 2025 ; 15( 9): 2583-2594.[citado 2026 maio 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/89159 - Validation of a Skin-Lesion Image-Matching Algorithm Based on Computer Vision Technology
- Immunofluorescence testing in the diagnosis of autoimmune blistering diseases: overview of 10-year experience
- Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey
- Some good and some bad: sand fly salivary proteins in the control of Leishmaniasis and in Autoimmunity
- Direct immunofluorescence findings and thrombophilic factors in livedoid vasculopathy: how do they correlate? [Carta]
- Linear IgA bullous dermatosis: report of an exuberant case
- From Insect Bites to a Skin Autoimmune Disease: A Conceivable Pathway to Endemic Pemphigus Foliaceus
- Diagnosis and management of pemphigus: recommendations of an international panel of experts
- Clinicopathologic correlation of 282 leukocytoclastic vasculitis cases in a tertiary hospital: a focus on direct immunofluorescence findings at the blood vessel wall
- Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
